Literature DB >> 1684975

Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users.

U D McCann1, G A Ricaurte.   

Abstract

Two persons are described who demonstrated prolonged neuropsychiatric syndromes after the ingestion of large doses of (+-)-3,4-methylenedioxymethamphetamine (MDMA), a recreationally used amphetamine analog. These cases suggest that MDMA, known to be neurotoxic to serotonin neurons in several experimental animals, may also produce untoward effects in humans. In addition, they provide evidence that ingestion of large doses of MDMA can produce lasting adverse functional consequences in vulnerable persons.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1684975

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


  12 in total

Review 1.  Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.

Authors:  Antonio Verdejo-García; Francisca López-Torrecillas; Carmen Orozco Giménez; Miguel Pérez-García
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

2.  Ecstasy and neurodegeneration. Tablets often contain substances in addition to, or instead of, ecstasy...

Authors:  A R Winstock; L A King
Journal:  BMJ       Date:  1996-08-17

Review 3.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

Review 4.  Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').

Authors:  U D McCann; S O Slate; G A Ricaurte
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 5.  Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners.

Authors:  G Huether; D Zhou; E Rüther
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

6.  Effects of acute 3,4-methylenedioxymethamphetamine on sleep and daytime sleepiness in MDMA users: a preliminary study.

Authors:  Surilla Randall; Chris-Ellyn Johanson; Manuel Tancer; Timothy Roehrs
Journal:  Sleep       Date:  2009-11       Impact factor: 5.849

7.  Reckless behaviour related to the use of 3,4-methylenedioxymethamphetamine (ecstasy): apropos of a fatal accident during car-surfing.

Authors:  P J Hooft; H P van de Voorde
Journal:  Int J Legal Med       Date:  1994       Impact factor: 2.686

8.  3,4-Methylenedioxy-N-methamphetamine (ecstasy) promotes the survival of fetal dopamine neurons in culture.

Authors:  Jack W Lipton; Emeline G Tolod; Valerie B Thompson; Lin Pei; Katrina L Paumier; Brian T Terpstra; Kaari A Lynch; Timothy J Collier; Caryl E Sortwell
Journal:  Neuropharmacology       Date:  2008-07-04       Impact factor: 5.250

Review 9.  Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").

Authors:  A R Green; A J Cross; G M Goodwin
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

10.  Serotonergic neurotoxic thioether metabolites of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): synthesis, isolation, and characterization of diastereoisomers.

Authors:  Nieves Pizarro; Rafael de la Torre; Jesús Joglar; Noriko Okumura; Ximena Perfetti; Serrine S Lau; Terrence J Monks
Journal:  Chem Res Toxicol       Date:  2008-12       Impact factor: 3.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.